Tiago Torres, EADV 2020 – The IL-23 Pathway in Psoriasis

We were delighted to have the opportunity to speak with Expert Faculty member Tiago Torres (Centro Hospitalar Universitário do Porto, Portugal) about the biology of the IL-23 pathway in psoriasis and the therapeutic use of IL-23 inhibitors.

Questions

1. Could you give us a brief overview of the role of the IL-23 in the pathogenesis of psoriasis? (1:46)
2. What clinical evidence supports the use of selective IL-23 inhibitors in the treatment of psoriasis? (2:50)
3. What are the main safety risks associated with IL‐23 inhibitors in patients with psoriasis? (3:56)
4. How is the role of IL-23 inhibitors likely to evolve in the future? (4:28)

Disclosures: Tiago Torres has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of the 29th EADV Virtual Congress 2020.